修订版马尔可夫模型评估良性指征子宫切除术时行卵巢切除术:重新审视65岁年龄界值
本研究通过文献综述获取按疾病、年龄、子宫切除术伴或不伴双侧输卵管卵巢切除术(BSO)及雌激素治疗使用的死亡风险比,结合国家生命统计数据的基线死亡率,构建马尔可夫模型预测45至55岁手术人群活到80岁的比例。结果显示,50岁前切除卵巢且未用雌激素者活到80岁的比例低于单纯子宫切除术者(52.8% vs 63.5%);50岁及以上两者比例相似(66.4% vs 66.9%);50岁前切除卵巢者使用雌激素后,心血管疾病、卒中及活到80岁的比例与单纯子宫切除术或50岁及以上切除卵巢者相似。
要点
- 50岁前行双侧输卵管卵巢切除术且未用雌激素者活到80岁的比例低于单纯子宫切除术者。
- 50岁及以上行子宫切除术时同期行双侧输卵管卵巢切除术者活到80岁的比例与单纯子宫切除术者相似。
- 50岁前需行双侧输卵管卵巢切除术者启动雌激素治疗可减轻增加的死亡风险。
核心结论
- 修订版马尔可夫模型支持考虑对50岁及以上行子宫切除术的患者同期行双侧输卵管卵巢切除术,并提示50岁前需行双侧输卵管卵巢切除术者启动雌激素可减轻增加的死亡风险。
研究设计与样本
- 研究通过文献综述评估按疾病、年龄、子宫切除术伴或不伴双侧输卵管卵巢切除术及雌激素治疗使用的死亡风险比,基线死亡率取自国家生命统计数据,构建马尔可夫模型预测45至55岁手术人群活到80岁的比例。
主要发现
- 50岁前行双侧输卵管卵巢切除术且未用雌激素者活到80岁的比例为52.8%(贝叶斯置信区间40.7-59.7),低于单纯子宫切除术者的63.5%(贝叶斯置信区间62.2-64.9)。
- 50岁及以上行单纯子宫切除术者活到80岁的比例为66.4%(贝叶斯置信区间65.0-67.6),与同期行双侧输卵管卵巢切除术者的66.9%(贝叶斯置信区间64.4-69.0)相似。
- 50岁前行双侧输卵管卵巢切除术者使用雌激素后,心血管疾病、卒中及活到80岁的比例与单纯子宫切除术或50岁及以上行子宫切除术加双侧输卵管卵巢切除术者相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform an updated Markov modeling to assess the optimal age for bilateral salpingo-oophorectomy (BSO) at the time of hysterectomy for benign indication. METHODS: We performed a literature review that assessed hazard ratios (HRs) for mortality by disease, age, hysterectomy with or without BSO, and estrogen therapy use. Base mortality rates were derived from national vital statistics data. A Markov model from reported HRs predicted the proportion of the population staying alive to age 80 years by 1-year and 5-year age groups at time of surgery, from age 45 to 55 years. Those younger than age 50 years were modeled as either taking postoperative estrogen or not; those 50 and older were modeled as not receiving estrogen. Computations were performed with R 3.5.1, using Bayesian integration for HR uncertainty. RESULTS: Performing salpingo-oophorectomy before age 50 years for those not taking estrogen yields a lower survival proportion to age 80 years than hysterectomy alone before age 50 years (52.8% [Bayesian CI 40.7-59.7] vs 63.5% [Bayesian CI 62.2-64.9]). At or after age 50 years, there were similar proportions of those living to age 80 years with hysterectomy alone (66.4%, Bayesian CI 65.0-67.6) compared with concurrent salpingo-oophorectomy (66.9%, Bayesian CI 64.4-69.0). Importantly, those taking estrogen when salpingo-oophorectomy was performed before age 50 years had similar proportions of cardiovascular disease, stroke, and people living to age 80 years as those undergoing hysterectomy alone or those undergoing hysterectomy and salpingo-oophorectomy at age 50 years and older. CONCLUSION: This updated Markov model argues for the consideration of concurrent salpingo-oophorectomy for patients who are undergoing hysterectomy at age 50 and older and suggests that initiating estrogen in those who need salpingo-oophorectomy before age 50 years mitigates increased mortality risk.
引用
- Rush SK, Ma X, Newton MA, et al. A Revised Markov Model Evaluating Oophorectomy at the Time of Hysterectomy for Benign Indication: Age 65 Years Revisited. Obstet Gynecol. 2022. PMID: 35576331. doi:10.1097/AOG.0000000000004732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。